The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...
A recent study hints at the popularity of different psoriasis treatments based on the number of mentions each received on two widely used social media forums. Researchers analyzed all posts entered on ...
Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...
Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses the challenges clinicians face when managing psoriasis in patients who also have metabolic syndrome.
NEW YORK — No fewer than four investigative therapies, ranging from an oral interleukin-23 receptor antagonist to oral tyrosine kinase inhibitors and a long-acting biologic, have the potential to ...
INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R ...
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in ...
From acne to sunburns, your skin is vulnerable to a range of uncomfortable conditions. Among them is psoriasis, which often appears on the face and body and can have a negative impact on your quality ...
Is Psoriasis an Autoimmune Disease? Yes, psoriasis is an autoimmune disease. It's also chronic and relapsing, which means you’ll have it long-term, but symptoms may come and go. Unlike a simple rash, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results